C11-TDP43-A382T
The cell line is not validated yet.
UQi001-A-1
General
Cell Line |
|
| hPSCreg name | UQi001-A-1 |
| Cite as: | UQi001-A-1 (RRID:CVCL_D0P9) |
| Alternative name(s) |
C11-TDP43-A382T
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UQi001-A (C11-WT) WTSIi018-B-21 (Kolf 2.1 J (TARDBP M337V SNV/SNV)) WTSIi018-B-22 (Kolf 2.1 J (TARDBP Q331K WT/SNV)) WTSIi018-B-23 (Kolf 2.1 J (TARDBP Q331K SNV/SNV)) WTSIi018-B-18 (Kolf 2.1 J (TARDBP M337V WT/SNV)) UCSFi001-A-74 (FUS-P525L HET 2D1) UCSFi001-A-75 (FUS-P525L HOM 2D2) WTSIi018-B-24 (Kolf 2.1 J (FUS R495X WT/SNV)) WTSIi018-B-25 (Kolf 2.1 J (FUS R495X SNV/SNV)) WTSIi018-B-26 (Kolf 2.1 J (FUS R521H WT/SNV)) WTSIi018-B-27 (Kolf 2.1 J (FUS R521H SNV/SNV)) UCSFi001-A-72 (FUS-R521G HET 2B10, LSUHSi004-A-72) UCSFi001-A-73 (FUS-R521G HOM 1D9) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-17 (BIONi010-C TREM2 KO) CBIGi001-A-1 (PRKN-KO, PRKN-KO/AIW002-02, IPSC0070) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) WAe001-A-76 (H1-RNF1-/-) CBIGi001-A-2 (PINK1-KO, PINK1-KO/AIW002-02, IPSC0072) CBIGi001-A-3 (PINK1-KO/PRKN-KO/AIW002-02, PINK1-KO/PRKN-KO, IPSC0069) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) |
| Last update | 16th May 2023 |
| User feedback | |
Provider |
|
| Generator | The University of Queensland (UQ) |
| Owner | The University of Queensland (UQ) |
| Distributors | |
| Derivation country | Australia |
External Databases |
|
| BioSamples | SAMEA113429835 |
| Cellosaurus | CVCL_D0P9 |
| Wikidata | Q123033758 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA113429809 |
Ethics
Also have a look at the ethics information for the parental line
UQi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UQi001-A.
|
|
| Passage number reprogrammed | 41 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ Plus
|
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
Synonyms
Genetic modifications
TARDBP (target)Isogenic modification
|
Login to share your feedback, experiences or results with the research community.